
CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.
Evaluation of more than 65,000 trials and 350,000 investigator sites highlights significant exposure in oncology and late-stage development.
The ongoing disruption in the Middle East is affecting a meaningful portion of global clinical research, with 6.7% of active trials and thousands of investigator sites exposed to regional instability, new insights from Phesi reveal.1






